Radex Heraklith Industriebeteiligungs (Germany)
- Research works
- 7 ▼ 80% vs 2013–17
- Citations
- 77 11.0 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 35% world 28%
Not ranked overall: Radex Heraklith Industriebeteiligungs (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which research topics does Radex Heraklith Industriebeteiligungs (Germany) publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, Advanced Breast Cancer Therapies and Breast Cancer Treatment Studies.
- 1 Cancer Immunotherapy and Biomarkers Oncology 0 works
- 2 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 0 works
- 3 Breast Cancer Treatment Studies Cancer Research 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Radex Heraklith Industriebeteiligungs (Germany)'s research output changed?
Output in 2018–2022 was 80% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Wiesbaden
- Helios Dr. Horst Schmidt Kliniken Wiesbaden
- Hologic (Germany)
- RheinMain University of Applied Sciences
- EBS University of Business and Law
- Deutsche Klinik für Diagnostik
- Statistisches Bundesamt
- Abbott (Germany)
- St. Josefs Hospital
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.